Trial Profile
A Phase III Prospective, Randomized, Double-Blind, Active-Controlled, Multi-Center, Superiority Study of Vernakalant Injection Versus Amiodarone in Subjects With Recent Onset Atrial Fibrillation.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Mar 2022
Price :
$35
*
At a glance
- Drugs Vernakalant (Primary) ; Amiodarone
- Indications Atrial fibrillation
- Focus Registrational; Therapeutic Use
- Acronyms AVRO
- Sponsors Correvio Pharma
- 29 Jun 2012 Company added in the association field as reported by EudraCT.
- 29 Jun 2012 Additional trial location (Latvia) identified as reported by EudraCT.
- 24 Mar 2012 This trial is recruiting in France.